Last verified: April 2026

What Is a Cannabinoid?

The term “cannabinoid” encompasses three distinct categories of compounds that interact with the endocannabinoid system:

• Phytocannabinoids — produced by Cannabis sativa (and, in some cases, other plants). Over 100 distinct phytocannabinoids have been identified, though most occur in trace amounts. The major phytocannabinoids — THC, CBD, CBN, CBG, CBC, and THCV — account for the vast majority of pharmacological research
• Endocannabinoids — produced endogenously by the body. The two principal endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG), both arachidonic acid derivatives. Additional endocannabinoid-like molecules include virodhamine, noladin ether, and N-arachidonoyl dopamine (NADA)
• Synthetic cannabinoids — laboratory-synthesized compounds. These range from FDA-approved pharmaceuticals (dronabinol, nabilone) to research tools (WIN 55,212-2, CP55,940) to illicit products (K2/Spice) that pose severe safety risks

All phytocannabinoids are terpenophenolic compounds — they contain a resorcinol (phenol) core with a terpene-derived side chain. They are lipophilic (fat-soluble), which determines their pharmacokinetic behavior: high oral bioavailability variability, extensive first-pass metabolism, accumulation in adipose tissue, and prolonged elimination half-lives.

The Biosynthetic Pathway: From CBGA to Everything Else

All major phytocannabinoids originate from a single precursor: cannabigerolic acid (CBGA), often called the “mother cannabinoid.” The biosynthetic pathway proceeds as follows:

1. Geranyl pyrophosphate (GPP) + olivetolic acid → CBGA, catalyzed by geranylpyrophosphate:olivetolate geranyltransferase (GOT)
2. CBGA is then converted by three competing synthase enzymes:
   • THCA synthase → THCA (tetrahydrocannabinolic acid)
   • CBDA synthase → CBDA (cannabidiolic acid)
   • CBCA synthase → CBCA (cannabichromenic acid)
3. These three acidic cannabinoids then undergo non-enzymatic decarboxylation (heat, light, time) to yield their neutral forms: THC, CBD, and CBC

The relative activity of these three synthase enzymes determines the chemotype of a given cannabis plant — whether it is THC-dominant, CBD-dominant, or balanced. This is genetically determined and represents the single most important variable in cannabis pharmacology. A plant’s chemotype is set by its genome; cultivation techniques can optimize yield but cannot fundamentally change which synthase pathway dominates.

CBG (cannabigerol) — the neutral form of CBGA — typically accumulates to only about 1% of dry weight in mature cannabis plants because CBGA is efficiently converted to downstream products. Specialized “CBG cultivars” have been bred with reduced synthase activity, allowing CBGA/CBG to accumulate.

Decarboxylation: Acid to Neutral Forms

The living cannabis plant produces cannabinoids almost exclusively in their acidic forms — THCA, CBDA, CBCA, CBGA. These carboxylic acid precursors are converted to their pharmacologically active neutral forms through decarboxylation: the loss of a carboxyl group (-COOH) as CO₂.

Decarboxylation occurs through:

• Heat — smoking (~600–900°C) produces near-complete decarboxylation; vaporization (~180–220°C) produces substantial but variable decarboxylation; oven decarboxylation for edible preparation typically uses ~110°C for 30–45 minutes
• Time — slow room-temperature decarboxylation occurs over weeks to months during storage and curing
• Light — UV exposure accelerates decarboxylation and also promotes THC oxidation to CBN

This distinction is pharmacologically critical. THCA cannot cross the blood-brain barrier efficiently and does not produce intoxication at typical doses because the carboxylic acid group prevents effective CB1 binding. Raw cannabis juice, which contains primarily acidic cannabinoids, does not produce the psychoactive effects associated with heated cannabis. The acidic cannabinoids have their own pharmacological profiles — CBDA, for example, shows remarkable potency at 5-HT1A receptors at concentrations 100–1,000 times lower than CBD (Bolognini et al., 2013, British Journal of Pharmacology).

Chemotypes and the Spectrum of Cannabis Varieties

Cannabis plants are classified into chemotypes based on their dominant cannabinoid profile:

• Chemotype I — THC-dominant (THC:CBD ratio > 1). Most recreational and many medical cannabis varieties. THC content in modern cultivars routinely exceeds 20–30% by dry weight
• Chemotype II — Mixed THC/CBD (roughly 1:1 ratio). Increasingly favored in medical cannabis programs. The pharmaceutical Sativex (nabiximols) approximates this ratio
• Chemotype III — CBD-dominant (CBD:THC ratio > 1). Industrial hemp is defined in U.S. law as cannabis with <0.3% THC by dry weight. Charlotte’s Web, the cultivar that launched the CBD movement, was bred as a 30:1 CBD:THC chemotype

Additional chemotype classifications include Chemotype IV (CBG-dominant, with reduced synthase activity) and Chemotype V (virtually no cannabinoids, essentially fiber hemp).

The historical shift from low-potency cannabis (<5% THC in the 1970s–80s) to modern high-potency cultivars (25–35% THC) reflects deliberate breeding pressure toward Chemotype I extremes. This potency escalation has significant implications for dose-response relationships, adverse effect profiles, and the applicability of older clinical data to contemporary cannabis products.

Why Structure Determines Pharmacology

The pharmacological differences between cannabinoids arise from remarkably small structural variations. THC and CBD share the same molecular formula (C₂₁H₃₀O₂) and nearly identical molecular weights, but differ in the arrangement of a single ring: THC has a closed pyran ring that enables it to fit the CB1 binding pocket, while CBD’s open ring prevents effective CB1 engagement. This single structural distinction is why THC produces intoxication and CBD does not.

Similarly, Δ⁸-THC and Δ⁹-THC differ only in the position of a single double bond (at carbon 8 vs. carbon 9), yet this shift reduces CB1 affinity by approximately 50%. CBN, formed by oxidation of THC, retains the pyran ring but loses aromaticity in the cyclohexene ring, reducing CB1 affinity to roughly one-tenth that of THC (Ki ≈ 211 nM vs. Ki ≈ 6.62–40.7 nM).

These structure-activity relationships underscore a fundamental principle: cannabinoid pharmacology is not a matter of “cannabis does X.” Each cannabinoid is a distinct pharmacological agent with its own receptor affinity profile, metabolic pathway, and dose-response characteristics. Treating “cannabis” as a single drug is as imprecise as treating “antibiotics” as a single drug — and just as likely to produce misleading conclusions.

The plant produces a pharmacopoeia, not a single drug. Each cannabinoid has its own receptor affinity profile, its own metabolic pathway, and its own clinical implications.

Raphael Mechoulam, Annual Review of Pharmacology and Toxicology, 2005